文献速递主动脉疾病

GORE EXCLUDER Conformable 内支架在成角瘤颈中关键试验亚组的早期结果

Early results from the pivotal trial substudy of the GORE EXCLUDER conformable endoprosthesis in angulated necks.
PubMed 文献 · J Vasc Surg · 2024-09-17

这项前瞻性多中心美国临床试验评估 GORE EXCLUDER Conformable AAA 内支架在肾下腹主动脉瘤伴高成角瘤颈(>60°且≤90°)患者中的1年结局。95例患者中技术成功率达97.9%,12个月主要有效性无事件率为94.8%,无动脉瘤相关死亡、破裂或移位,结论认为该装置在此类瘤颈中安全有效。

要点

  • 高成角瘤颈(>60°且≤90°)患者中技术成功率为97.9%(93/95)。
  • 12个月主要有效性无事件率为94.8%,无动脉瘤相关死亡、破裂或移位。
  • 4.3%(4例)出现IA型内漏,均无需干预且无后续内漏或瘤囊增大。

核心结论

  • 该研究显示 GORE EXCLUDER Conformable AAA 内支架在高度成角瘤颈(>60°且≤90°)的腹主动脉瘤中安全有效,且12个月随访时这些结果得以保持。

研究设计与样本

  • 前瞻性、多中心临床试验,在美国开展,包含影像核心实验室评估和独立事件裁定。
  • 高成角瘤颈亚组入组解剖标准为肾下主动脉瘤颈成角>60°且≤90°,且瘤颈长度≥10 mm。
  • 2018年1月至2022年2月期间,在35个中心共入组95例患者。
  • 95例患者中71例(74.7%)为男性,队列平均年龄74.4岁。
  • 平均肾下近端主动脉瘤颈角度为71.6°,平均腹主动脉瘤大小为62.9 mm。

主要发现

  • 总体技术成功在93例(97.9%)患者中实现。
  • 30天内主要安全性终点无事件率为96.7%;3例(3.3%)患者估计失血量>1000 mL。
  • 12个月时主要有效性无事件率为94.8%。
  • 4例(4.3%)患者出现IA型内漏,术后无需干预,这些患者未观察到后续干预或瘤囊增大。
  • 12个月时,29例(39.7%)患者出现II型内漏,1例(1.3%)患者出现腹主动脉瘤囊增大≥5 mm;截至12个月,1例(1.3%)患者转为开放手术修复。

关键数值与推荐

  • 高成角瘤颈亚组入组标准:肾下主动脉瘤颈成角>60°且≤90°,瘤颈长度≥10 mm。
  • 主要安全性终点包括估计失血量>1000 mL、死亡、卒中、心肌梗死、肠缺血、截瘫、呼吸衰竭、肾衰竭和血栓栓塞事件。
  • 主要有效性终点包括技术成功、无I型和III型内漏、移位(≥10 mm)、瘤囊增大(≥5 mm)、瘤囊破裂和转为开放修复。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the investigational device exemption study 1-year clinical outcomes of the high neck angulation (HNA) substudy of the GORE EXCLUDER Conformable AAA Endoprosthesis (EXCC) for treatment of infrarenal abdominal aortic aneurysms (AAAs). METHODS: This study is a prospective, multicenter clinical trial conducted in the United States and included core laboratory assessment of imaging and independent event adjudication. Anatomical criteria for enrollment in the HNA substudy included infrarenal aortic neck angulation >60° and ≤90° with aortic neck length ≥10 mm. Primary safety end points included estimated blood loss of >1000 mL, death, stroke, myocardial infarction, bowel ischemia, paraplegia, respiratory failure, renal failure, and thromboembolic events. Primary effectiveness end points included technical success, absence from type I and III endoleaks, migration (≥10 mm), sac enlargement (≥5 mm), sac rupture, and conversion to open repair. RESULTS: Between January 2018 and February 2022, 95 patients were enrolled in the HNA substudy across 35 sites. Of the 95 patients, 71 (74.7%) were male and the cohort average age was 74.4 years. The mean infrarenal proximal aortic neck angle was 71.6° and the mean AAA size was 62.9 mm. Overall technical success was achieved in 93 patients (97.9%). Freedom from a primary safety end point through 30 days was 96.7%; 3 (3.3%) patients had an estimated blood loss of >1000 mL. Freedom from the primary effectiveness at 12 months was achieved in 94.8%. Four patients (4.3%) had a type IA endoleak; intervention after the procedure was not required and no subsequent interventions or sac enlargement were noted in these patients. At 12 months, 29 patients (39.7%) experienced a type II endoleak and 1 (1.3%) patient experienced AAA sac expansion of ≥5 mm. Through 12 months, 1 patient (1.3%) had a conversion to open surgical repair. There were no aneurysm-related deaths, ruptures, or migration through 12 months. CONCLUSIONS: The investigational device exemption study demonstrates safety and effectiveness of the GORE EXCLUDER Conformable AAA Endoprosthesis device in AAA with highly angulated necks (>60° and ≤90°) are preserved at the 12-month follow-up.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Rhee RY, Almadani MW, Yamanouchi D, et al. Early results from the pivotal trial substudy of the GORE EXCLUDER conformable endoprosthesis in angulated necks. J Vasc Surg. 2024. PMID: 39299529. doi:10.1016/j.jvs.2024.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。